[{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Dermatology","graph2":"Phase I","graph3":"TWi Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"TWi Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TWi Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Extended-Release Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK1\/JAK2","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Progenity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Children\u2019s Hospital Los Angeles","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Lorazepam","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Children\u2019s Hospital Los Angeles","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"","sponsorNew":"Children\u2019s Hospital Los Angeles \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"Children\u2019s Hospital Los Angeles \/ National Institutes of Health"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"TWi Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"TWi Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TWi Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"14","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"}]
Find Clinical Drug Pipeline Developments & Deals for Xeljanz
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
